Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Dabrafenib + Trametinib in Advanced Melanoma
NCT02130466Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- May 2014
- Primary completion
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in melanoma, solid tumor, sponsored by Merck & Co.. Started May 2014; status: completed.
02
Drugs
03
Conditions
melanomasolid tumor
Beyond the preview
Go deeper on NCT02130466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02130466.